Empowering the next generation of Biopharma Pioneers.
For over two decades, Dr. Ratnesh Jain has mentored M.Tech and PhD scholars who now lead R&D, manufacturing, regulatory and strategy roles across Indian and global biopharma. His laboratory serves as an incubator for rigorous scientific inquiry and practical application.
Primary Areas of Research
Bioprocess Technology
Optimization of upstream and downstream processes for biologics manufacturing.
New Approach Methodologies (NAMs)
Organ-on-chip platforms for preclinical testing and safety assessment.
Monoclonal Antibodies (mAbs)
Development and optimization of therapeutic antibodies and biosimilars.
Cell & Gene Therapy (CGT)
Advancing the manufacturing and delivery of regenerative medicinal products.
Select Alumni Trajectories
Translating Laboratory Breakthroughs to Global Markets.
Many of Dr. Jain's students and collaborators have gone on to build ventures in biologics, devices, NAMs and digital health. He supports them in shaping technology, business models and regulatory strategy.
Priyanjali Maria Dias
Founder - Nexcure Biologics
Innovation for Rare & Unmet Medical Needs. Nexcure Biologics focuses on developing novel biologics for rare diseases and unmet medical needs.
Architecting the Future of Biotech.
Dr. Jain serves as a strategic bridge for deep-tech startups, providing the technical validation and operational guidance required to scale complex biological ventures.
Due Diligence
Helping Venture Capital firms evaluate the scientific viability and scalability of biopharma candidates through comprehensive technical assessments.
Operational Roadmap
Setting up scalable GLP labs and bioprocessing units that meet international regulatory standards for seamless technology transfer.
Regulatory Strategy
Developing comprehensive regulatory pathways for novel biologics and complex generics to accelerate market approval.
Tech Transfer
Facilitating seamless technology transfer from lab to commercial manufacturing with minimal loss of yield or quality.
Fundraising Support
Preparing investor decks and scientific narratives that effectively communicate the value proposition of biotech ventures.
Manufacturing Scale-up
Guiding process optimization for commercial-scale production while maintaining product quality and regulatory compliance.
Notable Venture Engagements
Global Collaboration & Technical Support.
Dr. Jain provides strategic consulting to biopharma companies, helping them navigate complex regulatory landscapes, optimize manufacturing processes, and accelerate product development. His expertise spans from early-stage research to commercial-scale production.
Strategic Consulting Focus
Bioprocess Development
Optimization of mAbs, vaccines, and peptide manufacturing processes for efficiency and regulatory compliance.
Tech Transfer & Scale-Up
Enabling seamless technology transfer and manufacturing scale-up for India and regulated global markets.
Regulatory & Scientific Support
Scientific support for regulatory filings, agency interactions, and CMC strategy for FDA/EMA-ready programs.
Due Diligence & Review
Technical due diligence and investment review for biopharmaceutical assets and licensing opportunities.
Outcomes & Impact
- Supported FDA/EMA-ready development for selected biologic programs
- Helped companies de-risk CMC strategies and accelerate timelines
- Enabled cost-effective, globally competitive manufacturing from India
- Guided regulatory interactions for complex biologic and peptide filings
- Developed regulatory strategies for complex generics and biosimilars
- Conducted technical due diligence assessments for biopharma investments
- Implemented quality by design principles across manufacturing facilities
- Trained professionals in advanced bioprocess technologies
The Mumbai Biocluster.
Mumbai Biocluster is a hub-and-spoke platform that we are building to accelerate regulatory approval and commercialization of next-generation therapies from India – spanning biologics, NAMs, rare diseases and cell and gene therapies.
Our Mission
Capacity building and training
For next-generation biopharma talent
Shared translational R&D infrastructure
And bioprocess platforms
Regulatory readiness programs
For biologics, NAMs and advanced therapies
Investor-connect and industry–academia interfaces
To accelerate commercialization
Our Vision
"To become a thriving hub that fosters cutting-edge research, nurtures innovation and creates a platform that would translate early-stage start-up and academic innovations into clinical stage biotechnology companies."
What the Biocluster Offers
Training & Skilling
Hands-on programs for bioprocess engineers, regulatory scientists, and translational researchers.
Translational R&D
Bioprocess platforms for mAbs, vaccines, peptides, and cell/gene therapy enabling research.
NAMs & Organoid Capabilities
Organ-on-chip, organoid models, and new approach methodologies for preclinical innovation.
Industry-Academia-Investor Interfaces
Structured interactions connecting research labs, companies, and capital for translational outcomes.
Partner with Us
Explore co-investment, strategic partnerships, and program-based collaborations with Mumbai Biocluster.
Get in TouchICT Mumbai Research Foundation, India
Single-use cGMP Facility
State-of-the-art facility for bioprocess development and pilot manufacturing with:
- Modular cleanroom suites
- Single-use bioreactor systems
- Downstream processing capabilities
- Analytical development labs
Curated Collaboration Hubs.
Dr. Jain curates platforms where regulators, industry leaders, and scientists converge to unlock collaborations, deals and policy direction. These initiatives have facilitated over 120 partnerships and $45M in funding connections.
Biologics Workshop Series
Quarterly Deep-Dive Sessions
Read MoreFlagship series focused on biosimilars, mAbs, and vaccines with regulatory roundtables featuring CDSCO, US-FDA, and EMA representatives. Each session includes:
Outcomes